Perrigo licenses meth-resistant tech for PSE products
DUBLIN, Ireland — Perrigo Co. plc is bringing in methamphetamine-blocking capability for pseudoephedrine (PSE) products. On Tuesday, Perrigo said it has entered an exclusive licensing agreement with St. Louis-based Highland Pharmaceuticals for its Tarex meth-blocking technology. The deal also includes the distribution rights of Zephrex-D, the pseudoephedrine nasal decongestant marketed by Highland’s Westport Pharmaceuticals unit.
